Anixa, OntoChem advance development of COVID-19 therapeutic

By The Science Advisory Board staff writers

April 5, 2021 -- Anixa Biosciences and OntoChem are progressing to the next stage of development of an antiviral therapy for COVID-19.

The therapy will be orally administered and room-temperature stable. The two firms have completed proof-of-concept animal studies that evaluated potential compounds and compared them with remdesivir.

The firms plan to use combinatorial synthetic medicinal chemistry to evaluate whether potency can be increased and pharmacokinetics optimized. Promising compounds will again be studied, they said. This stage of development will take four to five months.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.